Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

FY20 result: API (ASX:API) suffers from big profit hit

Australian Pharmaceutical Industries Ltd (ASX:API) has reported its FY20 result, which included a heavy profit decline. 

Australian Pharmaceutical Industries Ltd (ASX: API) has reported its FY20 result, which included a heavy profit decline.

API’s difficult FY20 year

API reported that statutory earnings before interest and tax (EBIT – click here to learn what EBIT means) was $4.4 million and reported net profit after tax was actually a loss of $7.9 million.

The statutory result included the write down of the Soul Pattinson Chemist brand name of $37.5 million as well as restructuring costs totaling $12.3 million.

Total revenue was $4 billion, an increase of 0.2%. Online sales grew by 69% compared to FY19, with more than 100% online sales growth since March.

Its underlying EBIT fell 40.1% to $56.3 million and underlying net profit after tax (NPAT), excluding AASB 16, was $32.5 million, down 42.6% on the prior corresponding period (pcp) because of retail lockdowns and reduced foot traffic.

On the positive side of things, cash conversion days reduced to 16.8, an improvement of 4.2 days in FY19. The cost of doing business also improved by 0.70% (70 basis points) to 10.2%.

Priceline company-owned stores (non-pharmacy) and Clear Skincare clinics were closed for up to 17 weeks with a reopening in Victoria apparently imminent. Clear Skincare launched a new website that boosted online sales.

The company said there was a significant shift in consumer spending towards products and services that address physical and mental wellbeing, and also towards value-based products which fit well with API’s offering. That meant there was a shift away from high margin categories including colour cosmetics and cold & flu medicine.

API dividend

The API board decided to declare a final dividend of 2 cents per share, which represents a 33% payout ratio of underlying net profit. The company didn’t pay an interim dividend due to COVID-19 concerns about preserving cash.

Outlook

Management believe API is well positioned for 2021 and beyond, it’s looking to secure more efficiencies in the coming year.

Priceline Pharmacy can do well from the shift to value based beauty and health products and services. The company expects to expand its network in 2021 as more independent pharmacies look for benefits that its brand and systems deliver to the bottom line.

API says that it has all the capex it needs to fully exploit the growth opportunities for its various divisions.

The company couldn’t give guidance, but it said that all the fundamentals are in place to deliver strong forward momentum.

According to CommSec, it’s priced at 12 times the estimated earnings for the 2021 financial year, with a projected fully franked yield of 5.9% from an estimated annual dividend of 6.2 cents per share. If that happens, then API could deliver good total returns over the next 12 months.

But I’m not sure about its long term profit growth prospects. That’s why I would rather buy other ASX dividend shares like Brickworks Limited (ASX: BKW) which could also see a good recovery of earnings over the next 12 months.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned.
Skip to content